ORIC Pharmaceuticals, Inc.
ORIC
Updated: 23/09/2026, 08:28:30
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
No summaries found.
- Share price
- $13.50
- Market cap
- $1.40B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jacob Chacko
- Employees
- 111
- IPO date
- 24/04/2020
- Beta
- 0.991
- Last dividend
- $0.00
- Day range
- $12.70 – $13.54
- 52-week range
- $7.23 – $14.93
- 1-day performance
- 6.55%
- 1-year performance
- 86.72%
- Current drawdown (1Y)
- -9.58%
- CIK
- 0001796280
- CUSIP
- 68622P109
- ISIN
- US68622P1093
- Created
- 07/12/2025, 05:37:36
- Last update
- 23/09/2026, 08:28:30
Track ORIC Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move ORIC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 09/06/2026, 15:02:14
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 05/06/2026, 18:30:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
PRNewsWire • STOCK • 21/05/2026, 18:40:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
GlobeNewsWire • STOCK • 19/05/2026, 19:33:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
PRNewsWire • STOCK • 14/05/2026, 22:15:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
GlobeNewsWire • STOCK • 12/05/2026, 19:41:00
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire • STOCK • 01/05/2026, 18:30:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
PRNewsWire • STOCK • 01/05/2026, 00:40:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
GlobeNewsWire • STOCK • 21/04/2026, 18:40:00
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewsWire • STOCK • 17/04/2026, 18:05:00
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Business Wire • STOCK • 16/04/2026, 00:58:00
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC
GlobeNewsWire • STOCK • 14/04/2026, 19:01:00